Mundipharma Drug Patent Portfolio
Mundipharma owns 1 orange book drug protected by 7 US patents Given below is the list of Mundipharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11197909 | Compositions and methods for the treatment of fungal infections | 14 Jul, 2038 | Active |
| US11819533 | Compositions and methods for the treatment of fungal infections | 11 Jul, 2038 | Active |
| US11712459 | Dosing regimens for treatment of fungal infections | 15 Mar, 2037 | Active |
| US10702573 | Dosing regimens for echinocandin class compounds | 14 Mar, 2033 | Active |
| US9526835 | Dosing regimens for echinocandin class compounds | 14 Mar, 2033 | Active |
| US11654196 | Dosing regimens for echinocandin class compounds | 02 Mar, 2032 | Active |
| US8722619 | Antifungal agents and uses thereof | 02 Mar, 2032 | Active |
Latest Legal Activities on Mundipharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mundipharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Election Required | 24 Jun, 2025 | US10702573 |
| Notice of Final Determination -Election Required | 24 Jun, 2025 | US9526835 |
| Notice of Final Determination -Election Required | 24 Jun, 2025 | US8722619 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 May, 2025 | US11197909 |
| FDA Final Eligibility Letter | 20 May, 2025 | US8722619 |
| FDA Final Eligibility Letter | 20 May, 2025 | US10702573 |
| FDA Final Eligibility Letter | 20 May, 2025 | US9526835 |
| Change in Power of Attorney (May Include Associate POA) | 01 Nov, 2024 | US8722619 |
| Email Notification | 01 Nov, 2024 | US8722619 |
| transaction for FDA Determination of Regulatory Review Period | 16 Sep, 2024 | US9526835 |
| transaction for FDA Determination of Regulatory Review Period | 16 Sep, 2024 | US10702573 |
| transaction for FDA Determination of Regulatory Review Period | 16 Sep, 2024 | US8722619 |
| transaction for FDA Determination of Regulatory Review Period | 22 Aug, 2024 | US9526835 |
| transaction for FDA Determination of Regulatory Review Period | 22 Aug, 2024 | US8722619 |
| transaction for FDA Determination of Regulatory Review Period | 22 Aug, 2024 | US10702573 |
Mundipharma's Family Patents
Mundipharma drugs have patent protection in a total of 23 countries. It's US patent count contributes only to 27.3% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Mundipharma Drug List
Given below is the complete list of Mundipharma's drugs and the patents protecting them.
1. Rezzayo
Rezzayo is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11197909 | Compositions and methods for the treatment of fungal infections |
14 Jul, 2038
(12 years from now)
| Active |
| US11819533 | Compositions and methods for the treatment of fungal infections |
11 Jul, 2038
(12 years from now)
| Active |
| US11712459 | Dosing regimens for treatment of fungal infections |
15 Mar, 2037
(11 years from now)
| Active |
| US10702573 | Dosing regimens for echinocandin class compounds |
14 Mar, 2033
(7 years from now)
| Active |
| US9526835 | Dosing regimens for echinocandin class compounds |
14 Mar, 2033
(7 years from now)
| Active |
| US11654196 | Dosing regimens for echinocandin class compounds |
02 Mar, 2032
(5 years from now)
| Active |
| US8722619 | Antifungal agents and uses thereof |
02 Mar, 2032
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rezzayo's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List